Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT01016834

Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine

Conditions: Migraine

Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: No
Phase: PHASE4
Enrollment: 246
Sponsor: Zogenix, Inc.

Location: University of Alabama Hospital, Dept. of Neurology Birmingham Alabama

Summary

The purpose of the study is to evaluate the treatment satisfaction of subjects using Sumavel DosePro to treat their moderate to severe migraines.

Eligibility Criteria

Inclusion Criteria: * History of 2 to 6 migraine headaches per month * Migraines should have been present for at least 1 year with age at onset of migraine less than 50 years * History of 24 hours of freedom between migraine attacks * Current users of triptan medications * Able to distinguish interval or other non-migrainous headaches from typical migraine * General good health Exclusion Criteria: * History or symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes * Significant underlying cardiovascular diseases including uncontrolled hypertension * Hemiplegic or basilar migraine * History or diagnosis of severe hepatic or renal impairment * History of epilepsy or seizure or other serious neurologic condition * History of allergy, anaphylaxis, or hypersensitivity to sumatriptan or any of its components or similar drugs including sulphonamides * History of scleroderma (systemic sclerosis) * Pregnant or breastfeeding * Use of contraindicated prescription medications, monoamine oxidase inhibitors (MAO-A), selective serotonin reuptake inhibitors, or lithium agents

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT01016834). StuddyBuddy aggregates publicly available trial information.